Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation

NEW YORK, NY--(Marketwired - Aug 6, 2013) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at http://www.crystalra.com.

International Stem Cell Corporation ("ISCO" or "the Company") is a biotechnology company focused on therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and eye, as well as on the development and commercialization of biomedical products. According to the Company, hpSC is the only histocompatible stem cell platform capable of generating stem cell lines that can immune-match millions of people. ISCO has focused its therapeutic efforts in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue: (1) Parkinson's disease (PD); (2) inherited metabolic liver disease; and (3) corneal blindness. The Company believes these markets may have a combined revenue potential of over $5 billion.

ISCO is also developing a stem cell bank, UniStemCell, which already contains enough histocompatible stem cell lines to immune-match over 75 million people. In addition, the Company produces and markets specialized cells and growth media for therapeutic research through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care. Revenue generated from ISCO's subsidiaries -- which totaled $4.6 million in 2012 -- supports the development of the Company's therapeutic programs. ISCO believes that its proprietary technology platform and business model result in three key competitive advantages: immune-matching stem cells, proven cell therapy targets, and substantial revenue from commercial operations.

Be the first to hear about Crystal Research's new reports and media coverage. Follow us on Twitter at http://twitter.com/crystalresearch or visit http://crystalra.com/blog/ for more coverage.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional-quality research on small- and mid-cap companies for the past decade. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street as well as for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

Crystal Research Associates' unique and novel product, the Executive Informational Overview (EIO), is free of investment ratings, target prices, and forward-looking financial models. The EIO presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO details a company's product/technology/service offerings, market size(s), intellectual property, leadership, growth strategy, competition, risks, financials, key events, and other fundamental information. Crystal Research Associates has offices in New York City and West Palm Beach. Crystal Research Associates has been compensated by the Company in cash of sixty-three thousand U.S. dollars for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic news and reports and filings with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

See the original post here:
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation